{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-035651","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.867458+00:00","generated_at":"2026-05-16T18:27:29.808140+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Genprex adds Gabrail Cancer Center as new site for Acclaim-1 and Acclaim-3 Reqorsa trials","bullets":["Gabrail Cancer Center (Canton, OH) is new clinical trial site for Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC) studying Reqorsa gene therapy.","Acclaim-1 Phase 2 expansion to enroll ~33 patients; interim analysis after 19 patients, enrollment of first 19 expected H1 2026.","Acclaim-3 Phase 2 expansion to enroll ~50 patients; interim analysis after 25th patient, enrollment of first 25 expected H1 2026.","Both trials have FDA Fast Track Designation; Acclaim-3 also has Orphan Drug Designation.","Phase 1 showed no dose-limiting toxicities and early efficacy: some patients had prolonged progression-free survival, one partial response."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-035651","json":"https://secwatch.observer/filing/0001437749-25-035651.json","markdown":"https://secwatch.observer/filing/0001437749-25-035651.md","text":"https://secwatch.observer/filing/0001437749-25-035651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925035651/0001437749-25-035651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925035651/gnpx20251116c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:27:29.808140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}